YD Bio Limited reports governance changes and a listing status update. On January 16, 2026, the Board appointed Dr. Chang as Chairman of the Compensation Committee and as a member of the Audit Committee and the Nominating and Corporate Governance Committee. On the same date, Dr. Lu was appointed Chairman of the Nominating and Corporate Governance Committee and as a member of the Audit Committee and Compensation Committee.
The company states that Dr. Chang and Dr. Lu have no material related-party interests, arrangements, or family relationships requiring disclosure under specified SEC regulations. On January 20, 2026, YD Bio notified Nasdaq that it has regained compliance with Audit Committee requirements under Nasdaq Listing Rule 5605 and is no longer in a cure period under Listing Rule 5605(c)(4)(B).
YD Bio Limited reports a change in its independent auditor. On September 16, 2025, the company ended its engagement with CBIZ CPAs P.C. as its independent registered public accounting firm, with the decision approved by both the audit committee and the board of directors.
CBIZ CPAs’ reports on YD Bio’s consolidated financial statements since inception on February 6, 2024 contained no adverse or disclaimed opinions and were not qualified, although they included an explanatory paragraph raising substantial doubt about the company’s ability to continue as a going concern. The company states there were no disagreements with CBIZ CPAs on accounting, disclosure, or audit matters, and none of the specified reportable events under Item 16F of Form 20-F occurred.
Effective September 17, 2025, YD Bio engaged ARK Pro CPA & Co as its new independent registered public accounting firm for the fiscal year ending December 31, 2025, with no prior consultations on accounting or audit opinions reported.